IL151321A0 - Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof - Google Patents

Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Info

Publication number: IL151321A0
Authority: IL; Israel
Prior art keywords: azetidine derivatives; preparation; pharmaceutical compositions; compositions containing; novel
Prior art date: 2000-03-03

Application number

IL15132101A

Other languages

English (en)

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-03

Filing date

2001-03-01

Publication date

2003-04-10

2001-03-01 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2003-04-10 Publication of IL151321A0 publication Critical patent/IL151321A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)

IL15132101A 2000-03-03 2001-03-01 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof IL151321A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0002776A FR2805817B1 (fr)	2000-03-03	2000-03-03	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
PCT/FR2001/000602 WO2001064634A1 (fr)	2000-03-03	2001-03-01	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Publications (1)

Publication Number	Publication Date
IL151321A0 true IL151321A0 (en)	2003-04-10

Family

ID=8847706

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15132101A IL151321A0 (en)	2000-03-03	2001-03-01	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
IL151321A IL151321A (en)	2000-03-03	2002-08-18	Pharmaceutical preparations containing azethidine derivatives, new azethidine derivatives and method of preparation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL151321A IL151321A (en)	2000-03-03	2002-08-18	Pharmaceutical preparations containing azethidine derivatives, new azethidine derivatives and method of preparation

Country Status (36)

Country	Link
EP (1)	EP1263722B1 (hu)
JP (1)	JP4883867B2 (hu)
KR (1)	KR100819572B1 (hu)
CN (1)	CN100386314C (hu)
AT (1)	ATE478841T1 (hu)
AU (1)	AU780880B2 (hu)
BG (1)	BG66001B1 (hu)
BR (1)	BR0108893B1 (hu)
CA (1)	CA2400141C (hu)
CY (1)	CY1111071T1 (hu)
CZ (1)	CZ301254B6 (hu)
DE (1)	DE60142891D1 (hu)
DK (1)	DK1263722T3 (hu)
DZ (1)	DZ3312A1 (hu)
EA (1)	EA007109B1 (hu)
EE (1)	EE05103B1 (hu)
ES (1)	ES2351276T3 (hu)
FR (1)	FR2805817B1 (hu)
HR (1)	HRP20020712B1 (hu)
HU (1)	HUP0400636A3 (hu)
IL (2)	IL151321A0 (hu)
MA (1)	MA26880A1 (hu)
ME (1)	MEP9509A (hu)
MX (1)	MXPA02008349A (hu)
NO (1)	NO324524B1 (hu)
NZ (1)	NZ521077A (hu)
OA (1)	OA12222A (hu)
PL (1)	PL208021B1 (hu)
PT (1)	PT1263722E (hu)
SI (1)	SI1263722T1 (hu)
SK (1)	SK287445B6 (hu)
TW (1)	TWI304399B (hu)
UA (1)	UA73554C2 (hu)
WO (1)	WO2001064634A1 (hu)
YU (1)	YU66002A (hu)
ZA (1)	ZA200206912B (hu)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001288972A1 (en)	2000-09-11	2002-03-26	Sepracor, Inc.	Antipsychotic sulfonamide-heterocycles, and methods of use thereof
US20020091114A1 (en)	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
FR2814678B1 (fr) *	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
WO2003007887A2 (en)	2001-07-20	2003-01-30	Merck & Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
FR2833842B1 (fr) *	2001-12-21	2004-02-13	Aventis Pharma Sa	Compositions pharmaceutiques a base de derives d'azetidine
AU2003217961B2 (en)	2002-03-08	2008-02-28	Signal Pharmaceuticals, Llc	Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
MXPA05000962A (es)	2002-07-29	2005-05-16	Hoffmann La Roche	Nuevos benzodioxoles.
CA2511905A1 (en)	2003-01-02	2004-07-22	F. Hoffmann-La Roche Ag	Novel cb 1 receptor inverse agonists
ES2334565T3 (es)	2003-01-02	2010-03-12	Hoffmann La Roche	Agonistas inversos del receptor cb 1.
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
EP1601665A2 (en) *	2003-03-07	2005-12-07	Glaxo Group Limited	Urea derivatives
CA2524245A1 (en) *	2003-05-01	2004-11-11	Vernalis Research Limited	The use of azetidinecarboxamide derivatives in therapy
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
BRPI0411131A (pt)	2003-06-11	2006-07-18	Merck & Co Inc	composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto
DE602004012858T2 (de)	2003-06-20	2009-05-14	F. Hoffmann-La Roche Ag	2-aminobenzothiazole als cb1 rezeptor inverse agonisten
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
EP1694673B1 (en)	2003-12-08	2008-01-16	F.Hoffmann-La Roche Ag	Thiazole derivates
DE602005023124D1 (de)	2004-01-28	2010-10-07	Hoffmann La Roche	Spirobenzodioxole und deren verwendung als cb1-antagonisten
EP1574211A1 (en)	2004-03-09	2005-09-14	Inserm	Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP1749002B1 (en)	2004-05-10	2009-05-27	F.Hoffmann-La Roche Ag	Pyrrole or imidazole amides for treating obesity
FR2876688B1 (fr) *	2004-10-14	2007-03-16	Aventis Pharma Sa	Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
FR2876689B1 (fr)	2004-10-14	2008-02-22	Aventis Pharma Sa	Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
BRPI0517369A (pt)	2004-10-27	2008-10-07	Hoffmann La Roche	compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
DE602005024430D1 (de)	2004-11-09	2010-12-09	Hoffmann La Roche	Dibenzosuberon-derivate
BRPI0609685A2 (pt)	2005-04-06	2010-04-20	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
JP5154927B2 (ja)	2005-05-30	2013-02-27	Ｍｓｄ株式会社	新規ピペリジン誘導体
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007018248A1 (ja)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	ピリドン化合物
US7875633B2 (en)	2005-08-24	2011-01-25	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1944301A4 (en)	2005-10-27	2012-01-04	Msd Kk	NEW BENZOXATHIIN DERIVATIVES
AU2006312557B2 (en)	2005-11-10	2011-12-08	Msd K.K.	Aza-substituted spiro derivative
US7906652B2 (en)	2005-11-28	2011-03-15	Merck Sharp & Dohme Corp.	Heterocycle-substituted 3-alkyl azetidine derivatives
AR058199A1 (es) *	2005-11-28	2008-01-23	Merck & Co Inc	Derivados de 3- alquilazetidina sustituidos con heterociclos
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7781593B2 (en)	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
CA2664113C (en)	2006-09-22	2013-05-28	Merck & Co., Inc.	Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (fr)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Dérivé diarylcétimine
WO2008120653A1 (ja)	2007-04-02	2008-10-09	Banyu Pharmaceutical Co., Ltd.	インドールジオン誘導体
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FR2925050B1 (fr) *	2007-12-14	2010-01-08	Sanofi Aventis	Nouveau procede de preparation de derives d'azetidine
PT2234966E (pt) *	2007-12-18	2013-12-19	Sanofi Sa	Derivados de azetidinas, sua preparação e sua aplicação em terapia
FR2930941B1 (fr) *	2008-05-06	2010-06-18	Sanofi Aventis	Derives d'azetidines, leur preparation et leur application en therapeutique
FR2928149B1 (fr)	2008-02-29	2011-01-14	Sanofi Aventis	Composes derives d'azetidines, leur preparation et leur application en therapeutique
AU2009229860A1 (en)	2008-03-28	2009-10-01	Msd K.K.	Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
AU2009256157B2 (en)	2008-06-04	2014-12-18	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diaryl ketoxime derivative technical field
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
FR2934996B1 (fr) *	2008-08-14	2010-08-27	Sanofi Aventis	Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique
FR2934995B1 (fr) *	2008-08-14	2010-08-27	Sanofi Aventis	Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
CA2741125A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (es)	2008-10-30	2011-11-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida
CN102271509A (zh)	2008-10-31	2011-12-07	默沙东公司	用于抗糖尿病药的新型环苯并咪唑衍生物
EP2358200A4 (en)	2008-11-17	2012-05-16	Merck Sharp & Dohme	BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
FR2946650B1 (fr) *	2009-06-16	2011-08-19	Sanofi Aventis	Esters derives d'azetidines, leur preparation et leur application en therapeutique.
WO2011011508A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011106273A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011137024A1 (en)	2010-04-26	2011-11-03	Merck Sharp & Dohme Corp.	Novel spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en)	2010-05-11	2011-11-17	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en)	2010-06-11	2013-11-27	Merck Sharp & Dohme	NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
KR101668514B1 (ko)	2011-02-25	2016-10-21	머크 샤프 앤드 돔 코포레이션	항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP4424697A2 (en)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CA2959208C (en)	2014-08-29	2023-09-19	Tes Pharma S.R.L.	Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CN109952292A (zh)	2016-10-14	2019-06-28	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
BR112021009589A2 (pt)	2018-11-20	2021-08-17	Tes Pharma S.R.L.	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2021329805B2 (en)	2020-08-18	2024-02-29	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4242261A (en) *	1979-07-19	1980-12-30	A. H. Robins Company, Inc.	Production of methylene-cycloamines
FR2649100B1 (fr) *	1989-06-29	1994-03-04	Laboratorios Dr Esteve Sa	Nouvelles azetidines, leur preparation et leur application comme intermediaires pour la preparation de composes avec activite antimicrobienne
US5556861A (en) *	1991-10-01	1996-09-17	Laboratoire Roger Bellon	1,8 benzonaphthyridine derivatives and antimicrobial compositions
JPH09500134A (ja) *	1993-07-16	1997-01-07	メルクエンドカンパニーインコーポレーテッド	ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤
US5545636A (en) *	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
US6022868A (en) *	1995-06-29	2000-02-08	Novo Nordisk Als	Substituted azacyclic or azabicyclic compounds
GB9714129D0 (en) *	1997-07-04	1997-09-10	Pfizer Ltd	Azetidines

2000
- 2000-03-03 FR FR0002776A patent/FR2805817B1/fr not_active Expired - Fee Related
2001
- 2001-01-03 UA UA2002097701A patent/UA73554C2/uk unknown
- 2001-02-23 TW TW090104187A patent/TWI304399B/zh not_active IP Right Cessation
- 2001-03-01 CZ CZ20022923A patent/CZ301254B6/cs not_active IP Right Cessation
- 2001-03-01 WO PCT/FR2001/000602 patent/WO2001064634A1/fr active IP Right Grant
- 2001-03-01 JP JP2001563477A patent/JP4883867B2/ja not_active Expired - Fee Related
- 2001-03-01 CA CA2400141A patent/CA2400141C/fr not_active Expired - Fee Related
- 2001-03-01 OA OA1200200270A patent/OA12222A/fr unknown
- 2001-03-01 SI SI200130981T patent/SI1263722T1/sl unknown
- 2001-03-01 DZ DZ013312A patent/DZ3312A1/fr active
- 2001-03-01 DK DK01909939.9T patent/DK1263722T3/da active
- 2001-03-01 DE DE60142891T patent/DE60142891D1/de not_active Expired - Lifetime
- 2001-03-01 CN CNB018066437A patent/CN100386314C/zh not_active Expired - Fee Related
- 2001-03-01 HU HU0400636A patent/HUP0400636A3/hu unknown
- 2001-03-01 AT AT01909939T patent/ATE478841T1/de active
- 2001-03-01 AU AU37527/01A patent/AU780880B2/en not_active Ceased
- 2001-03-01 ME MEP-95/09A patent/MEP9509A/xx unknown
- 2001-03-01 PL PL365046A patent/PL208021B1/pl unknown
- 2001-03-01 MX MXPA02008349A patent/MXPA02008349A/es active IP Right Grant
- 2001-03-01 NZ NZ521077A patent/NZ521077A/en unknown
- 2001-03-01 BR BRPI0108893-9A patent/BR0108893B1/pt not_active IP Right Cessation
- 2001-03-01 EP EP01909939A patent/EP1263722B1/fr not_active Expired - Lifetime
- 2001-03-01 EE EEP200200485A patent/EE05103B1/xx not_active IP Right Cessation
- 2001-03-01 IL IL15132101A patent/IL151321A0/xx unknown
- 2001-03-01 EA EA200200938A patent/EA007109B1/ru not_active IP Right Cessation
- 2001-03-01 KR KR1020027011517A patent/KR100819572B1/ko not_active IP Right Cessation
- 2001-03-01 YU YU66002A patent/YU66002A/sh unknown
- 2001-03-01 ES ES01909939T patent/ES2351276T3/es not_active Expired - Lifetime
- 2001-03-01 PT PT01909939T patent/PT1263722E/pt unknown
- 2001-03-01 SK SK1243-2002A patent/SK287445B6/sk not_active IP Right Cessation
2002
- 2002-08-18 IL IL151321A patent/IL151321A/en not_active IP Right Cessation
- 2002-08-28 MA MA26794A patent/MA26880A1/fr unknown
- 2002-08-28 ZA ZA200206912A patent/ZA200206912B/en unknown
- 2002-08-30 HR HRP20020712AA patent/HRP20020712B1/hr not_active IP Right Cessation
- 2002-09-02 NO NO20024177A patent/NO324524B1/no not_active IP Right Cessation
- 2002-09-03 BG BG107058A patent/BG66001B1/bg unknown
2010
- 2010-11-18 CY CY20101101042T patent/CY1111071T1/el unknown

Also Published As

Publication number	Publication date
CN1418192A (zh)	2003-05-14
YU66002A (sh)	2005-09-19
SK12432002A3 (sk)	2003-06-03
HRP20020712B1 (hr)	2012-11-30
HUP0400636A2 (hu)	2004-06-28
BG66001B1 (bg)	2010-09-30
PL208021B1 (pl)	2011-03-31
CZ301254B6 (cs)	2009-12-23
UA73554C2 (en)	2005-08-15
FR2805817B1 (fr)	2002-04-26
BG107058A (bg)	2003-07-31
BR0108893A (pt)	2002-11-05
TWI304399B (en)	2008-12-21
ES2351276T3 (es)	2011-02-02
AU780880B2 (en)	2005-04-21
NZ521077A (en)	2004-09-24
CY1111071T1 (el)	2015-06-11
PL365046A1 (en)	2004-12-27
KR100819572B1 (ko)	2008-04-04
DE60142891D1 (de)	2010-10-07
HRP20020712A2 (en)	2005-10-31
CA2400141C (fr)	2012-02-21
HUP0400636A3 (en)	2004-09-28
SI1263722T1 (sl)	2010-12-31
FR2805817A1 (fr)	2001-09-07
BR0108893B1 (pt)	2013-06-04
MXPA02008349A (es)	2002-12-13
MA26880A1 (fr)	2004-12-20
NO20024177L (no)	2002-10-29
EP1263722A1 (fr)	2002-12-11
WO2001064634A1 (fr)	2001-09-07
JP2003525270A (ja)	2003-08-26
NO20024177D0 (no)	2002-09-02
DK1263722T3 (da)	2011-01-03
CA2400141A1 (fr)	2001-09-07
AU3752701A (en)	2001-09-12
ZA200206912B (en)	2003-11-03
OA12222A (fr)	2006-05-10
ATE478841T1 (de)	2010-09-15
MEP9509A (en)	2011-12-20
EA200200938A1 (ru)	2003-02-27
DZ3312A1 (fr)	2001-09-07
NO324524B1 (no)	2007-11-12
SK287445B6 (sk)	2010-10-07
JP4883867B2 (ja)	2012-02-22
EA007109B1 (ru)	2006-06-30
PT1263722E (pt)	2010-11-23
CN100386314C (zh)	2008-05-07
EP1263722B1 (fr)	2010-08-25
EE200200485A (et)	2004-02-16
KR20020075469A (ko)	2002-10-04
EE05103B1 (et)	2008-12-15
IL151321A (en)	2008-11-03

Publication	Publication Date	Title
DZ3312A1 (fr)	2001-09-07	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
YU65802A (sh)	2005-11-28	Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
MXPA02012033A (es)	2003-04-25	Derivados de 2-aminocarbonil-9h-purina.
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NL350075I2 (hu)	2017-02-07
MXPA02003977A (es)	2003-09-25	Inhibidores de adhesion de celula mediada por al°2.
AP2002002637A0 (en)	2002-09-30	Novel piperazine
IL143545A0 (en)	2002-04-21	Thrombin inhibitors
GB9914486D0 (en)	1999-08-18	Medicaments
HK1076605A1 (en)	2006-01-20	Formulations
EP1340755A4 (en)	2004-03-17	AGENT WITH EFFECT AGAINST HELICOBACTER
MXPA05011176A (es)	2005-12-14	Derivados de carboxamida como agentes antidiabeticos.
EP1277744A4 (en)	2007-07-11	OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT
WO2001081316A3 (en)	2002-05-23	Substituted phenyl farnesyltransferase inhibitors
DE60114640D1 (en)	2005-12-08	Antithrombosemittel
MXPA05006889A (es)	2006-04-07	Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
YU72802A (sh)	2006-01-16	Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
CA2374643A1 (en)	2000-11-30	1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
WO2003086412A3 (fr)	2004-04-01	Derives poly-phosphonates pour compositions dentifrices
MY128457A (en)	2007-02-28	2-aminocarbonyl-9h-purine derivatives
AU1434201A (en)	2001-05-30	Antithrombotic agents